Bionet Therapeutics (ROCO:7808) Net Margin %: -57.48% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:7808 Bionet Therapeutics Corp ROCO:7808
12 GF Score
Price NT$31.00
! 2 Warning Signs
View Full Analysis

What is Bionet Therapeutics Net Margin %?

Bionet Therapeutics ROCO:7808 12 Net Margin % is -57.48% as of Dec. 2025. GuruFocus rates ROCO:7808 with a GF Score™ of 12/100. The stock has 2 warning signs investors should review. Among 941 Biotechnology companies, Bionet Therapeutics ranks better than 52.6% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Bionet Therapeutics's Net Income for the six months ended in Dec. 2025 was NT$-53.0 Mil. Bionet Therapeutics's Revenue for the six months ended in Dec. 2025 was NT$92.2 Mil. Therefore, Bionet Therapeutics's net margin for the quarter that ended in Dec. 2025 was -57.48%.

The historical rank and industry rank for Bionet Therapeutics's Net Margin % or its related term are showing as below:

ROCO:7808' s Net Margin % Range Over the Past 10 Years
Min: -695.44   Med: -106.07   Max: -63.07
Current: -63.07

ROCO:7808's Net Margin % is ranked better than
52.6% of 941 companies
in the Biotechnology industry
Industry Median: -88.29 vs ROCO:7808: -63.07

Bionet Therapeutics  (ROCO:7808) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Bionet Therapeutics Net Margin % Related Terms

Bionet Therapeutics Net Margin % Historical Data

* Premium members only.

The historical data trend for Bionet Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bionet Therapeutics Net Margin % Chart

Bionet Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Net Margin %
0.00 -695.44 -106.07 -63.07

Bionet Therapeutics Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Net Margin % Get a 7-Day Free Trial -448.18 -79.68 -129.18 -71.33 -57.48

ROCO:7808 vs VRTX, REGN, ALNY: Net Margin % Comparison

For the Biotechnology subindustry, Bionet Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bionet Therapeutics Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bionet Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Bionet Therapeutics's Net Margin % falls into.


ROCO:7808
12GF Score
Bionet Therapeutics Corp ROCO:7808
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bionet Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Bionet Therapeutics's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-97.426/154.478
=-63.07 %

Bionet Therapeutics's Net Margin for the quarter that ended in Dec. 2025 is calculated as

Net Margin=Net Income (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-52.977/92.163
=-57.48 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of -57.48% mean?
Bionet Therapeutics (ROCO:7808) has a Net Margin % of -57.48% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Bionet Therapeutics and its competitors. According to the industry distribution chart, Bionet Therapeutics ranks #446 out of 941 companies in the Biotechnology industry, placing it in the top 47.4%.
Is Bionet Therapeutics' Net Margin % too high?
Bionet Therapeutics' current Net Margin % is -57.48%. Based on the distribution chart, Bionet Therapeutics ranks #446 out of 941 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Bionet Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Bionet Therapeutics' Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bionet Therapeutics ranks #446 out of 941 companies for Net Margin %. This puts Bionet Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Bionet Therapeutics and its competitors. Bionet Therapeutics's current Net Margin % is -57.48%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bionet Therapeutics stock overvalued right now?
Bionet Therapeutics (ROCO:7808) has a current Net Margin % of -57.48%. The current Net Margin % is -57.48%. Bionet Therapeutics' overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Bionet Therapeutics (ROCO:7808), the current Net Margin % is -57.48% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bionet Therapeutics Business Description

Address No.28, Lane. 36 , Xinhu 1st Road, 1st Floor, Neihu District, Taipei, TWN, 11497
Bionet Therapeutics Corp is a patient-focused on regenerative medicinal products, R&D, exosomes, and gene/cell therapy biopharmaceutical company. The group develops, manufactures, and provides regenerative medicine preparations and cellular therapies to meet the evolving health needs of people at different stages of life. It focused on treatments that improve patient outcomes. It provides Cell Therapy Products and CRDMO Services.
12GF Score

Get the complete analysis for ROCO:7808

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$31.00
Price